PALB2 and neoplasm: Tumor response was assessed according to RECIST 1.1 criteria for measurable disease.<h4>Results</h4>All patients harbored pathogenic HRR gene alterations: somatic and/or germline BRCA1/2 (three BRCA2, two BRCA1), and one patient with concurrent PALB2.